Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics (Nasdaq: KLRS) will present Phase 1a clinical data for TH103, a dual-targeting VEGF/HSPG biologic for neovascular age-related macular degeneration, at the ASRS 2026 Annual Meeting on July 17, 2026, in Montréal.

Rhea-AI Summary

Kalaris Therapeutics (Nasdaq: KLRS) will present Phase 1a clinical data for TH103, a dual-targeting VEGF/HSPG biologic for neovascular age-related macular degeneration, at the ASRS 2026 Annual Meeting on July 17, 2026, in Montréal.

The company reports its Phase 1b/2 multiple ascending dose trial of TH103 in neovascular AMD is actively enrolling and dosing patients, with initial data expected in 1H 2027 to guide potential future Phase 3 dose selection.

Argus Jun 23 session

+1.59% close to close 0.3x rel. volume Open Argus

Details

News Market Reaction – KLRS

On Jun 23, the day this news came out, KLRS closed 1.59% above the previous close.

Data tracked by StockTitan Argus for the Jun 23 session.

Key Figures

Phase 1a data: Phase 1a Conference date: July 17, 2026 Presentation time: 8:00 am EDT +3 more

Phase 1a data

Phase 1a

Single ascending dose study of TH103 in treatment-naïve nAMD

Conference date

July 17, 2026

ASRS 2026 presentation of TH103 Phase 1a data

Presentation time

8:00 am EDT

ASRS 2026 TH103 Phase 1a session slot

Phase 1b/2 trial

Phase 1b/2

Multiple ascending dose nAMD study of TH103 actively enrolling

Initial data timing

1H 2027

Planned initial readout from Phase 1b/2 TH103 nAMD study

Future development

Phase 3

Phase 1b/2 data intended to inform potential future Phase 3 dose selection

Historical Context

4 past events · Latest: Jun 12

4 events

1. Jun 12

   Conference presentation

   24h Move

   +0.7%

   Announcement of Phase 1a TH103 data presentation at Clinical Trials Summit.

2. May 12

   Quarterly earnings

   24h Move

   +1.3%

   Q1 2026 results with TH103 progress and funding runway into Q4 2027.

3. Mar 17

   Annual results

   24h Move

   -3.3%

   Full-year 2025 results with positive Phase 1a nAMD data and financing.

4. Jan 28

   Clinical data presentation

   24h Move

   -2.6%

   Planned Phase 1 TH103 data presentation at Macula Society meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1a, phase 1b/2, dual-targeting vegf/hspg biologic, treatment-naïve, +2 more

6 terms

phase 1a medical

"announced an upcoming presentation of Phase 1a data at the American"

Phase 1a is the initial part of a human clinical trial where a new drug or therapy is given to a small group of people for the first time to check safety, how the body handles it, and to identify appropriate dosing. Investors watch phase 1a like a vehicle's first test drive: clear safety and predictable behavior reduce risk and unlock value by allowing larger, more expensive trials to proceed and by increasing the chance of regulatory progress.

phase 1b/2 medical

"its Phase 1b/2 multiple ascending dose study of TH103 for neovascular"

Phase 1b/2 is a combined early-stage human study that first checks a drug’s safety and side effects in a small group and then expands to test whether it shows signs of working in patients. Think of it as a product test that first confirms it’s safe to use, then looks for early evidence of benefit; positive results can significantly reduce clinical risk and increase a company’s value, while negative results raise the opposite.

dual-targeting vegf/hspg biologic medical

"TH103, a Novel Dual-Targeting VEGF/HSPG Biologic: Phase 1 Single"

A dual-targeting VEGF/HSPG biologic is a lab-made protein drug designed to block two molecules that help abnormal blood vessels grow and carry signals inside tissues: VEGF, a major growth signal, and HSPGs, sugar-coated scaffolds that help those signals stick and spread. For investors, this matters because hitting two related targets with one therapy can increase effectiveness or last longer than single-target drugs, potentially offering a competitive edge but also carrying higher development and regulatory risk.

treatment-naïve medical

"Single Ascending Dose Study in Treatment-Naïve Neovascular AMD"

Patients described as treatment-naïve have not previously received the therapy being studied or other prior treatments for the same condition, so their bodies are ‘untouched’ by those drugs. For investors, this matters because results in a treatment-naïve group show how a therapy performs without prior drug effects, influence trial design and regulatory labeling, and help estimate the size and profile of the initial market—like testing a new seed in a garden that has never been treated before.

neovascular amd medical

"Dose Study in Treatment-Naïve Neovascular AMDSpeaker: Joel Pearlman"

Neovascular AMD is an advanced form of age-related macular degeneration where abnormal, leaky blood vessels grow under the central part of the retina, causing rapid and severe loss of central vision; think of it like a leaking pipe damaging the most important part of a camera sensor. It matters to investors because treatments are often ongoing, high-cost medical therapies whose clinical trial results, regulatory approvals and reimbursement decisions can drive large, sustained revenues or sudden swings in a company’s valuation.

multiple ascending dose medical

"confirms that its Phase 1b/2 multiple ascending dose study of TH103"

A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced an upcoming presentation of Phase 1a data at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting.

ASRS Presentation Details:

• Title: First-in-Human Evaluation of TH103, a Novel Dual-Targeting VEGF/HSPG Biologic: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD
• Speaker: Joel Pearlman, MD, PhD, Retinal Consultants Medical Group
• Date: Friday, July 17, 2026
• Time: 8:00 am EDT
• Session: AMD - Neovascular Symposium 2. Innovations in nAMD: New Targets, New Therapies, Early Results
• Location: Palais des congrès de Montréal, Montréal, Quebec

Kalaris also confirms that its Phase 1b/2 multiple ascending dose study of TH103 for neovascular Age-related Macular Degeneration is actively enrolling and dosing patients.  The company remains on-track to share initial data from the study in 1H 2027 which is designed to accelerate TH103’s clinical development and inform dose selection for potential future Phase 3 development.

About TH103

TH103 is an investigational dual-targeting biologic engineered by VEGF scientific discoverer Dr. Napoleone Ferrara to achieve extended intraocular retention with enhanced VEGF inhibition through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring. It is a fully humanized, recombinant fusion protein designed for intravitreal delivery, with potential applications as a treatment for exudative and/or neovascular retinal diseases, such as wet AMD, diabetic eye disease and retinal vein occlusion. TH103 is currently being investigated in a Phase 1b/2 clinical trial in patients with neovascular Age-related Macular Degeneration (nAMD).

About Kalaris

Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.

For more information, visit www.kalaristx.com.

Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
cdavis@lifesciadvisors.com
ir@kalaristx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kalaris Therapeutics (KLRS) announce about TH103 at ASRS 2026?

Kalaris Therapeutics announced an upcoming presentation of Phase 1a clinical data for TH103 at the ASRS 2026 Annual Meeting. According to Kalaris, this first-in-human study evaluates a single ascending dose of TH103 in treatment-naïve neovascular AMD patients.

When and where will Kalaris (KLRS) present TH103 Phase 1a data?

Kalaris will present TH103 Phase 1a data on Friday, July 17, 2026, at 8:00 am EDT. According to Kalaris, the session will be held at the Palais des congrès de Montréal during the ASRS 2026 Annual Meeting.

What is TH103 and which condition is Kalaris (KLRS) targeting?

TH103 is described as a novel dual-targeting VEGF/HSPG biologic being developed for neovascular age-related macular degeneration. According to Kalaris, Phase 1a data come from a single ascending dose study in treatment-naïve neovascular AMD patients, informing early clinical development.

What is the status of Kalaris (KLRS) Phase 1b/2 trial of TH103?

The Phase 1b/2 multiple ascending dose study of TH103 in neovascular AMD is currently actively enrolling and dosing patients. According to Kalaris, this trial is intended to accelerate TH103’s development and help select doses for potential future Phase 3 studies.

When will Kalaris (KLRS) share initial Phase 1b/2 data for TH103?

Kalaris expects to share initial data from the Phase 1b/2 multiple ascending dose study of TH103 in the first half of 2027. According to Kalaris, these data are planned to inform dose selection for potential future Phase 3 development.

What session will feature Kalaris (KLRS) TH103 data at ASRS 2026?

TH103 Phase 1a data will be presented in the AMD - Neovascular Symposium 2: Innovations in nAMD: New Targets, New Therapies, Early Results. According to Kalaris, retinal specialist Joel Pearlman, MD, PhD, will deliver the presentation at ASRS 2026.